FAM182A

Across TCGA pan-cancer cohorts, FAM182A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM182A data layer compared with 17 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM182A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM182A expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and HNSC are the cancer types where FAM182A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.367	0.958	.010	7	view →
GBM	DFS	Tertile	All	0.657	0.177	.024	4	view →
HNSC	DFS	Quartile	All	0.842	1.000	.023	3	view →
LUAD	OS	Median	II,III,IV	0.227	0.764	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM182A–PDAC (DFS)

Open the PDAC breakdown →